I believe someone mentioned previously that Dr T was presenting at the end of last month so he may have just wrapped up, or still be in the midst of, presenting to US funds. They will obviously then research further and then if interested purchase. This is the whole reasoning for the Lanstead funding pause so if we dont see an appreciation in the SP between now and Xmas it is fair to say that the presentations did not achieve what they were set out to do- increase the SP.
Whilst i wouldn't bet the house on it i cant really see any bad news between now and the P3 trial commencement. That's not to say none will come. But im expecting announcements on the below:
- P2 studies published in peer review journal- this must be close. I emailed them in July and was advised manuscript had been submitted and they were just waiting on publication dates
- Toxicology results- cant see any issues here
- Potential pivotal trial for Fragile X
- Potential update on TBI trials
- Further development on NNZ-2591
- Enrollment and trial details for P3
Given our cash position i dont see any cap raises. Unless something comes from left field i struggle to see any bad news.
NEU Price at posting:
$1.25 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)